Drugs / Dextroamphetamine
Dextroamphetamine
also known as
D-amphetamine · Dexedrine · d-amphetamine sulfate · Dexamfetamine · Dexamphetamine · Dextroamphetamine Sulfate · Amfe-dyn · Amfetamine, (s)- · +31 more
Small molecule targets SLC18A2, SLC6A2, SLC6A3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ADDERALL 5 | — | 1960-01-19 | fda.gov ↗ |
Trials 37 · a red edge is where a trial was stopped
19581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031
Also used as a comparator or background therapy in 21 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04647903 Comparator | Oct 2020 → Dec 2021 | attention deficit-hyperactivity disorder, narcolepsy | Vallon Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03200080 Comparator | Sep → Nov 2017 | substance abuse | Biotie Therapies Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03103750 Background | Aug 2017 → Jan 2023 | attention deficit-hyperactivity disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT02515955 Background | Aug 2015 → Mar 2016 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT02144415 Comparator | May → Jul 2014 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02033707 Background | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00611936 Background | Jun 2006 → Aug 2007 | — | Yale University | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT05790239 Comparator | Mar 2025 → Mar 2026 overdue | post-traumatic stress disorder | Stephen Robert Marder | Recruiting | No outcome recorded |
| Phase 2 | NCT04414930 Comparator | Nov 2020 → Dec 2024 | schizoaffective disorder, schizophrenia | University of California, San Diego | Completed | No outcome recorded |
| Phase 2 | NCT02634684 Comparator | Jul 2014 → Aug 2020 | schizophrenia | University of California, San Diego | Completed | No outcome recorded |
| Phase 2 | NCT01711021 Comparator | Oct 2012 → Mar 2013 | attention deficit-hyperactivity disorder | Noven Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01399827 Comparator | Feb 2012 → Nov 2017 | attention deficit-hyperactivity disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01215929 Comparator | Oct 2009 → Apr 2013 | methamphetamine dependence | University of Arkansas | Completed | No outcome recorded |
| Phase 2 | NCT02203786 Comparator | Sep 2009 → Jun 2015 | pathological gambling | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 2 | NCT00630682 Comparator | Sep 2006 → Mar 2009 | methamphetamine dependence | California Pacific Medical Center Research Institute | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02204410 Background | Jul 2014 → May 2016 | attention deficit-hyperactivity disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01985581 Background | Oct 2013 → Mar 2015 | attention deficit-hyperactivity disorder | JPM van Stralen Medicine Professional | Completed | No outcome recorded |
| Phase 4 | NCT00228046 Background | Jan 2004 → Jul 2007 | attention deficit-hyperactivity disorder, conduct disorder, oppositional defiant disorder | Stony Brook University | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT01577706 Comparator | Jun → Dec 2013 | — | Mclean Hospital | Terminated | No outcome recorded |
| — | NCT02142140 Comparator | Dec 2012 → Feb 2019 | attention deficit-hyperactivity disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| — | NCT02210728 Comparator | Apr 2006 → Oct 2018 | attention deficit-hyperactivity disorder | Lily Hechtman | Unknown | No outcome recorded |
Evidence & citations 47 cited values
Every value below carries the sentence it was read from. 61 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dextroamphetamine | “Objectives: To assess efficacy and safety of the new Dextroamphetamine Transdermal System (d-ATS) to treat children and adolescents (aged 6-17 years) with...” PMID 35020462 ↗ Jan 202222“The purpose of this study is to determine if administration of dextroamphetamine (amph) linked with customarily used Rehabilitation Medicine accelerates motor recovery after stroke.” NCT00001783 ↗ “Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression” NCT00296686 ↗ “Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine” NCT00794625 ↗ “Dextroamphetamine” NCT00573859 ↗ “Dextroamphetamine” NCT01399827 ↗ |
| Known as | Amfe-dyn | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Amfetamine, (s)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | amph | “The purpose of this study is to determine if administration of dextroamphetamine (amph) linked with customarily used Rehabilitation Medicine accelerates motor recovery after stroke.” NCT00001783 ↗ |
| Known as | Bar-dex | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | d-amph | “BRS function was probed in 20 AD patients using dextroamphetamine (d-amph) challenge.” PMID 18591575 ↗ Jul 2008 |
| Known as | D-amphetamine | “The study hypothesis is that dextro-amphetamine (d-amphetamine) will be safe and effective when used to augment treatment for Obsessive-Compulsive Disorder (OCD)” NCT00363298 ↗20“Two stimulant medications, modafinil and d-amphetamine, when tested individually, have shown safety and efficacy for treatment of cocaine addiction.” PMID 22969732 ↗ Aug 2012 “Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion” NCT02033707 ↗ “Irritation and Sensitization Study of d-Amphetamine Transdermal System” NCT04094025 ↗ “20 mg/70 kg (20 mg maximum) dose of d-amphetamine will be measured” NCT00611936 ↗ “d-Amphetamine: 40.3mg p.o, single dose” NCT02668926 ↗ |
| Known as | D-amphetamine hemisulfate salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | d-amphetamine sulfate | “d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)” NCT01886469 ↗ |
| Known as | d-ATS | “Objectives: To assess efficacy and safety of the new Dextroamphetamine Transdermal System (d-ATS) to treat children and adolescents (aged 6-17 years) with...” PMID 35020462 ↗ Jan 2022 |
| Known as | Depalone | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dexamfetamine | “There is evidence that stimulants such as dexamfetamine and methylphenidate lead to an improvement in sustained focused attention, working memory, and a variety of cognitive...” NCT06967857 ↗ |
| Known as | Dexamfetamine phosphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dexamfetamine sulfate | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dexamfetamine sulphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02363075 ↗ |
| Known as | Dexampex | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dexamphetamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05529927 ↗ |
| Known as | Dexamphetamine sulfate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04968522 ↗ |
| Known as | Dexamphetamine sulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dexanfetamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dexedrine | “patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)” NCT01985581 ↗8“Dextroamphetamine (Dexedrine), gel-capsule, 20mg, single-dose, 1-day” NCT01577706 ↗ “Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)” NCT00697138 ↗ “Dexedrine” NCT02210728 ↗ “Dexedrine” NCT02566824 ↗ “Dexedrine” NCT02142140 ↗ “Dexedrine” NCT02204410 ↗ |
| Known as | Dexedrine spansule | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dexedrine Spansules | “d-Amphetamine sustained release (SR) (Dexedrine Spansules) started at 15 mg (day 1-2), increased to 30mg (day3; 15mg, BID), 45mg (day4; 15mg, TID), and 60mg (day5; 15mg bid...” NCT00218062 ↗ |
| Known as | Dexidrine | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dextroamphetamine adipate component of delcobese | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | DEXTROAMPHETAMINE PHOSPHATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dextroamphetamine resin complex | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dextroamphetamine saccharate component of mydayis | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dextroamphetamine Sulfate | “Dextroamphetamine Sulfate From an Abuse-Deterrent Immediate-Release Formulation (ADAIR)” NCT04232644 ↗ |
| Known as | Dextroamphetamine sulfate cii | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dextroamphetamine sulfate component of delcobese | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dextroamphetamine sulfate component of mydayis | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dextroamphetamine sulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Dextrostat | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | Ferndex | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | NSC-27104 | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | NSC-73713 | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Known as | SR-Dexamphetamine | “After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of...” NCT05529927 ↗ |
| Known as | Sustained-release Dexamphetamine | “Drug: Sustained-release Dexamphetamine” NCT05529927 ↗ |
| Known as | Xelstrym | ChEMBL registry synonym — accepted as the source's own label CHEMBL612 ↗ |
| Action | Activate | “used to stimulate dopamine release in the brain” NCT03349606 ↗ |
| Action | Inhibit | “Synaptic vesicular amine transporter inhibitor” CHEMBL612 ↗ |
| Modality | Small molecule | — CHEMBL612 ↗ |
| Route | Oral | “oral amphetamine” NCT00611936 ↗ |
| Target | SLC18A2 | “Synaptic vesicular amine transporter inhibitor” CHEMBL612 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter releasing agent” CHEMBL612 ↗ |
| Target | SLC6A3 | “Dopamine transporter releasing agent” CHEMBL612 ↗ |